诺华可善挺®放射学阴性中轴型脊柱关节炎适应症在华获批

Core Viewpoint - Novartis announced on February 3 that its innovative biological agent, Cosentyx, has received approval from the National Medical Products Administration for a new indication to treat adult patients with active radiographic axial spondyloarthritis who have inadequate response to non-steroidal anti-inflammatory drugs [1] Group 1 - The new indication is specifically for adult patients with active radiographic axial spondyloarthritis [1] - The approval is significant as it addresses a patient population that has not responded adequately to traditional non-steroidal anti-inflammatory drugs [1] - This development may enhance Novartis's position in the market for treatments targeting inflammatory conditions [1]